SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is experiencing intense volatility and a sharp multi-year price decline following a weak outlook and concerns over declining demand in China. While the community remains deeply divided, with some investors betting on a generational value play due to the brand's iconic status and dividend, others are aggressively shorting the stock, citing poor leadership, brand dilution, and concerns that the company's growth model is fundamentally broken.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is seeing heightened volatility and intense social media debate as investors react to the company's pause in Bitcoin accumulation and ongoing concerns regarding stock dilution. The community remains deeply polarized, with bulls pointing to the company's long-term Bitcoin treasury strategy while vocal critics argue that the reliance on equity offerings to fund operations creates an unsustainable path for shareholders.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

Restoration Hardware is experiencing significant volatility following a mixed quarterly report where revenue beat analyst estimates while earnings fell short of expectations. The community remains deeply divided, with bulls pointing to the company's long-term luxury ecosystem strategy and potential tariff relief as major catalysts, while bears warn of ongoing debt pressures, weakening housing trends, and a business model struggling to sustain high-end demand.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending following a surprise leadership overhaul that replaced CEO Peter Greenleaf with board chair Kevin Tang, a move widely interpreted by the community as a strategic catalyst for an accelerated company sale. Shareholders are actively debating whether Tangs decision to forgo compensation and his recent heavy accumulation of shares signals an imminent buyout or a shift toward aggressive value maximization.

Tema ETF Trust - Tema Space Innovators ETF

The Tema Space Innovators ETF (NASA) is gaining significant community attention as a new, pure-play vehicle offering direct exposure to SpaceX and other space exploration companies ahead of anticipated industry milestones. Investors are actively debating the fund's early AUM and liquidity, drawing frequent comparisons to other space-themed ETFs and speculating on potential price momentum as interest in commercial space activity intensifies.

Wingstop, Inc. is a franchisor and chicken wings-focused restaurant. The firm is engaged in the flavor business offering cooked-to-order, hand-sauced, and tossed classic and boneless wings, tenders and chicken sandwiches in flavors, with signature sides, such as its seasoned fries and house made ranch and bleu cheese dips. The company was founded in 1994 and is headquartered in Dallas, TX.

Wingstop Inc

Wingstop is experiencing intense volatility and downward pressure as investors debate whether the stock is an oversold growth opportunity or a bubble facing a severe consumer discretionary correction. While bullish participants point to the company's aggressive store expansion, share buybacks, and international potential as reasons to buy the dip, bears are aggressively shorting the stock, citing concerns over same-store sales declines, high valuations, and broader fears of consumer exhaustion impacting the restaurant sector.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is experiencing high volatility as investors track its history as a parabolic runner, leading to intense debate over whether it is primed for another short squeeze or remains a high-risk pump-and-dump scheme. Community discussion is heavily focused on the stock's low float, rising cost-to-borrow fees, and speculation regarding potential retail-driven "meme" momentum compared to its past price spikes.

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals is trending following a significant clinical update regarding its Phase 1b trial of rinzimetostat in combination with darolutamide for prostate cancer. While the stock faced an intraday slump due to concerns over safety signals at higher doses, community discussion remains heavily divided between those viewing the selloff as an exaggerated overreaction with upside potential and those concerned about the broader implications for EZH2-targeting drug classes.

SharonAI Holdings, Inc. engages in providing high-performance computing (HPC), artificial intelligence (AI), and cloud GPU compute infrastructure technologies. The company was founded on December 30, 2024 and is headquartered in New York, NY.

SharonAI Holdings Inc. - Ordinary Shares - Class A

SharonAI is experiencing heightened investor interest and speculative momentum following the announcement of a multi-year AI cloud infrastructure contract. The community is actively discussing the company's low-float structure and potential for a short squeeze, with many users weighing the risks of volatility and lack of volume against the company's long-term enterprise pipeline.

Hertz Global Holdings, Inc. engages in the vehicle rental business through the Hertz, Dollar, and Thrifty brands. It operates under the Americas Rental Car (RAC) and International Rental Car (RAC) segments. The Americas RAC segment focuses on operations in the United States, Canada, Latin America, and the Caribbean. The International RAC segment includes the provision of rental and sales of vehicles and value-added services in other locations. The company was founded in 1918 and is headquartered in Estero, FL.

Hertz Global Holdings Inc. - Ordinary Shares (New)

Hertz Global Holdings Inc

Hertz is seeing heightened volatility and investor speculation as traders debate the potential for a short squeeze, fueled by high short interest and anticipation surrounding upcoming earnings. The community remains sharply divided, with some betting on a long-term turnaround backed by Bill Ackmans significant stake, while others express frustration over persistent share price weakness and the company's substantial debt load.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CERo Therapeutics Holdings (CERO) announced on Friday that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to the company’s lead investigational compound, CER-1236, for Acute Myeloid Leukemia (AML).On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CERO">CERO stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:575/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_05_at_10_32_53_AM_png_e724743b98.webp" alt="CERO's Sentiment Meter and Message Volume as of 10:33 a.m. ET on Sept. 5, 2025 | Source: Stocktwits" width="575" height="64"><figcaption>CERO's Sentiment Meter and Message Volume as of 10:33 a.m. ET on Sept. 5, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects a "big bounce" for the stock soon.<stembedurl>https://stocktwits.com/pharmdavid13/message/627619560</stembedurl>FDA’s Fast Track Designation is designed to accelerate the development and review of therapies for serious or life-threatening conditions with unmet medical need. The designation provides CERo with the opportunity for increased FDA interactions, potential eligibility for priority review, and the ability to submit data on a rolling basis, it <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cero.bio/press-release?storyId=6780690611361163">said</a>.The new designation comes weeks after the FDA granted the experimental drug an Orphan Drug designation. The FDA's Orphan Drug program is designed to advance the development of drugs that treat rare conditions affecting 200,000 or fewer US patients annually.“These FDA designations are important additional validation with regard to the urgency of the condition as well as the potential that the agency sees in the existing data as submitted. Further, these designations help to decrease the potential time to market and provide additional benefits across the FDA process that are expected to prove both medically and financially valuable,” said CERo Therapeutics CEO Chris Ehrlich.The company is currently undertaking early-stage trials of CER-1236 in patients with acute myeloid leukemia. The study is designed to evaluate the safety and preliminary efficacy of the experimental cancer drug.Shares of the company, however, slumped 12% at the time of writing after the firm <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/1870404/000121390025084610/ea025606902-424b3_cero.htm">said</a> on Thursday that it recently received a letter from the Nasdaq Listing Qualifications department notifying the company that it does not comply with the minimum stockholders’ equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market.The Nasdaq staff indicated that the company’s securities would be suspended from trading on Nasdaq and delisted on Sept. 8, 2025. The company said that it subsequently requested a hearing to appeal the determination before a panel. The hearing request will stay the suspension of the trading of the company’s common stock and delisting thereof pending such hearing, it said.The company said that it intends to submit a plan to regain compliance with the Stockholders’ Equity Requirement at the hearing. Such a plan of compliance may include an increase in stockholders’ equity through the consummation of public or private financing transactions, the company said, while adding that there can be no assurances that it will obtain a favorable decision from the hearing panel.CERO stock is down by 95% this year and by 97% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/legend-biotech-considering-second-listing-outside-us-report/chwIifbRdqJ">Legend Biotech Considering Second Listing Outside US: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CERo Therapeutics Gets Fast Track Designation For Experimental Cancer Drug, But Stock Tumbles – Here’s What Happened

The new designation was granted weeks after the FDA awarded the experimental drug an Orphan Drug designation.

Equity

The new designation was granted weeks after the FDA awarded the experimental drug an Orphan Drug designation.


Shares of Cero Therapeutics Holdings drew increased retail investor chatter on Tuesday after the company said that the FDA granted orphan drug designation to its lead candidate, CER-1236, for treating acute myeloid leukemia (AML).The stock soared 189% to $19.83&nbsp;in the regular session, but fell by 15% in after-hours trading.The Phase 1/1b, open-label, multi-center clinical trial will assess the safety and initial efficacy of CER-1236 in patients with relapsed or refractory AML, remission with measurable residual disease, or newly diagnosed with TP53-mutated MDS/AML or AML.The study will include a dose escalation to determine the recommended Phase 2 dose and an expansion phase.Major objectives include the frequency of adverse events, dose-limiting toxicities, estimated overall and complete response rates, and measurable residual disease. Minor objectives include pharmacokinetics.The company said CER-1236 is designed to engineer a patient’s T cells to use phagocytic mechanisms — or target-cell “eating” — in addition to T cell destruction mechanisms.The Orphan Drug designation includes FDA assistance in clinical trial design, grants, a waiver of drug application fees, and seven years of market exclusivity upon approval.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.One user said they had accumulated shares from $8 to $15 and were still holding 4,700 shares, undecided on whether to carry the position overnight.&nbsp;<stembedurl>https://stocktwits.com/Dansaidso/message/618224240</stembedurl>Another user pointed to the stock's sharp gains, suggesting that after-hours moves were less meaningful for low-float names like Cero, which they believed could see additional upside.<stembedurl>https://stocktwits.com/SK444/message/618231176</stembedurl>Cero stock has declined 83.8% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Light micrograph of a section through a transitional cell carcinoma (TCC, cancer) of the bladder wall. | Image source: Getty Images

Cero Therapeutics Rockets On FDA Orphan Drug Status For Blood Cancer Drug; Retail Bulls Feel Stock 'Still Has A Few Pumps Left'

CER-1236 is designed to engineer T cells with phagocytic, or target-cell "eating," functions alongside traditional cancer-killing mechanisms. 

Biotech company CERo Therapeutics Holdings, Inc. (CERO) on Wednesday <a target="_blank" rel="noopener noreferrer nofollow" href="https://cero.bio/press-release?storyId=7625589476402466">announced</a> an agreement with the University of California Davis to manufacture its lead compound, CER-1236, which will be used in the company’s Phase 1 clinical trial for Acute Myeloid Leukemia (AML).The company said that the first patient is expected to be dosed in the first half of 2025.CEO Chris Ehrlich highlighted UC Davis’ precision and compliance in manufacturing, which is critical for the successful development and execution of clinical trials.“The manufacturing of product is among the final steps necessary to have completed prior to patient dosing, and we are looking forward to continuing to drive the process forward,” he said.The U.S. Food and Drug Administration (FDA) cleared the company’s application for phase 1 clinical trials of the compound in November.Earlier this month, during a scientific conference in San Diego, the company demonstrated that CER-1236 <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cero.bio/press-release?storyId=5472816266845157">treated</a> ovarian cancer cells without generating toxicity in animals.On Stocktwits, retail sentiment continues to trend in the ‘bullish’ territory (63/100) while message volume remains high.<figure class="image"><img style="aspect-ratio:811/177;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2025_03_19_101142_png_18b82101f9.webp" alt="CERo Therapeutics' Sentiment Meter and Message Volume as of 10:10 a.m. ET on March 19, 2025 | Source: Stocktwits" width="811" height="177"><figcaption>CERo Therapeutics' Sentiment Meter and Message Volume as of 10:10 a.m. ET on March 19, 2025 | Source: Stocktwits</figcaption></figure>At the end of 2024, the company faced delisting risks after its shares traded below Nasdaq’s minimum bid price requirement. Earlier this year, it announced a one-for-hundred reverse stock split of its common stock to increase its market price.In February, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://cero.bio/press-release?storyId=7680160497345168">raised $5 million</a> through a public offering.<a href="https://stocktwits.com/symbol/CERO">Shares of CERo</a> have dropped by over 80% year-to-date and about 100% in the past 12 months. On Wednesday morning, the stock opened over 2% lower.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/morgan-stanley-in-spotlight-after-reports-of-workforce-reduction/ch7kWQlRb2g">Morgan Stanley In Spotlight After Reports Of Workforce Reduction, Retail’s Yet To React</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic picture shows a hand holidng a capsule on 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

CERo Therapeutics Partners With University Of California Davis For Manufacturing Lead Compound For Treating Cancer: Retail Stays Bullish

The compound will be used in the company’s Phase 1 clinical trial for Acute Myeloid Leukemia, with the first patient expected to be dosed in the first half of 2025.

U.S. biotech stocks, particularly small and mid-cap companies, remained a focal point for retail investors in 2024 despite significant volatility.&nbsp;Collectively, biotech stocks on U.S. bourses have garnered over 3.3 million watchers on Stocktwits.&nbsp;Here are the top five biotech stocks that saw the most significant surge in new followers this year:CERo Therapeutics Holdings Inc. (CERO): +44544% WatchersThis immunotherapy company develops engineered T-cell therapeutics for cancer. <a href="https://stocktwits.com/symbol/CERO">CERO</a> saw major retail interest following the FDA’s clearance of its lead compound, CER-1236, for Phase 1 clinical trials after an earlier clinical hold. The company went public via a SPAC merger in February and has lost 99% of its value this year.Psyence Biomedical Ltd. (PBM): +6741% WatchersKnown for developing natural psilocybin products for treating psychological trauma, PBM gained attention for positive results from its Phase IIb trial in adjustment disorder treatment for terminal cancer patients.&nbsp;Its&nbsp;shares have also dropped 99% this year since the company’s March SPAC debut.Azitra Inc. (AZTR): +2365% WatchersSpecializing in dermatological therapies using engineered proteins and live biotherapeutic products, AZTR drew attention for securing&nbsp;a fast track designation for ATR-04 and other multiple&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-are-azitra-shares-trending-on-wednesday/c7r4UW0RbE">patents</a>. Its stock value has plunged more than 99% since its debut in June last year.Immuneering Corporation (IMRX): +2248% WatchersFocused on oncology, IMRX’s lead program, IMM-1-104, received FDA orphan drug designation for pancreatic cancer and fast-track status to treat certain melanoma patients, and is currently in a Phase 2a trial. <a href="https://stocktwits.com/symbol/IMRX">IMRX shares</a> have declined over 70% year-to-date.NKGen Biotech Inc. (NKGN): +1260% WatchersNKGN develops autologous and CAR-NK cell therapies. Its SNK01 natural killer cell therapy for Alzheimer’s disease showed promising results, with 90% of patients maintaining or improving cognitive function. The candidate was cleared to progress into phase 2 clinical development, which will involve a larger group of 30 patients with moderate Alzheimer's disease. Shares, however, have fallen more than 66% this year.Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments, positioning them as key biotech names to watch heading into 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Top 5 Biotech Stocks That Captured Retail Investor Interest The Most In 2024

Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments.

CERo Therapeutics Holdings, Inc. is an immunotherapy company, which engages in development of engineered T cell therapeutics for the treatment of cancer. Its platform is designed to redirect patient-derived T cells to eliminate tumors, creating Chimeric Engulfment Receptor T (CER-T) cells used for spanning hematological malignancies and solid tumors. The company was founded on June 8, 2021 and is headquartered in Oakland, CA.

CERo Therapeutics Holdings Inc.

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

CERO
CERo Therapeutics Holdings Inc

Feed

News

Sentiment

Fundamentals

Info

Latest CERO News

CEROCERo Therapeutics Holdings Inc